

Members Obtain Free CE Credits from JCP Articles!



A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome

September 2020 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19. Learners that complete this course will be able to understand the role of meropenem/vaborbactam when treating complicated urinary tract infections in patients with ESRD. Learners that complete this course will learn and explain a comprehensive review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.



Joint Accreditation Statement

In support of improving patient care, the American College of Clinical Pharmacology® (ACCP) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

UAN: JA4008220-0000-20-023-H01-P– ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this Journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the role of tocilizumab for potential treatment of COVID-19;
2. Discuss the efficacy and safety profile of tocilizumab in treating patients with COVID-19;
3. Define the study outcomes for COVID-19 treatment;
4. Identify the CYP450 metabolism of tocilizumab and potential drug-drug interactions.

Requirements to Receive Credit

In order to receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed

within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph S. Bertino Jr, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc. Nothing to disclose.

Planner: Michael W. Jann, PharmD, Professor, Pharmacotherapy, Univ of North Texas System Coll of Pharmacy. Nothing to disclose.

CE Reviewer: Steven J. Crosby, MA, Assistant Dean, Student Engagement & Success, MCPHS Univ. Nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 09/01/2020

Expiration Date: 12/31/2022

Helpful Tips

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).
